GU Cancers 2024 | Biomarkers for muscle-invasive bladder cancer in the AMBASSADOR trial

Andrea Apolo, MD, National Institutes of Health, Bethesda, MD, gives an overview of biomarkers associated with checkpoint inhibitors in the Phase III AMBASSADOR trial (NCT03244384) of adjuvant pembrolizumab in patients with muscle-invasive and locally advanced bladder cancer (MIBC). Whilst PD-L1 was identified as prognostic biomarker, where overall survival and disease-free survival were both correlated with PD-L1 expression, PD-L1 was not effective as a predicative biomarker. Correlative studies are underway to elucidate potential biomarkers such as circulating tumor DNA (ctDNA). This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.